Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Growing patent filings and tier-2 innovators reflect expanding national research base
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Subscribe To Our Newsletter & Stay Updated